Disseminated primary varicella infection during infliximab treatment

Journal of Rheumatology

Volumn 31, Issue 12, 2004, Pages 2517-2518

  Vonkeman, Harald ^a,b   Ten Napel, Chris ^a   Rasker, Hans ^a   Van De Laar, Mart ^a  

^a Department of Rheumatology ^*

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Infliximab treatment; Tumor necrosis factor ; Varicella infection

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CHICKENPOX; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ACYCLOVIR; ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CHICKENPOX; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; INJECTIONS, INTRAVENOUS; MALE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10044224715     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Ziolkowska M, Maslinski W. Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol 2003;15:267-73.
2. Ito M, Nakano T, Kamiya T, et al. Effects of tumor necrosis factor alpha on replication of varicella zoster virus. Antiviral Res 1991;15:183-92.
3. Straus SE, Ostrove JM, Inchauspe G, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med 1988;108:221-37.
4. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001;345:1098-104.
5. Ricart E, Pannaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001;96:722-9.
6. Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course-juveriile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218-26.